中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (9): 639-646.doi: 10.12144/zgmfskin202309639

• 论著 • 上一篇    下一篇

托法替尼治疗关节病型银屑病疗效及安全性Meta分析

胥杨1,赵菊花2   

  1. 1川北医学院附属医院皮肤科,四川南充,637000；2南充市中心医院皮肤科,四川南充,637000
  • 出版日期:2023-09-15 发布日期:2023-09-05

Efficacy and safety of tofacitinib in the treatment of psoriatic arthritis: a meta-analysis

XU Yang1, ZHAO Juhua2   

  1. 1 Department of Dermatology, the Affiliated Hospital of North Sichuan Medical College,Nanchong 637000, China; 2 Department of Dermatology, Nanchong Central Hospital, Nanchong 637000, China
  • Online:2023-09-15 Published:2023-09-05

PDF (PC)

48

摘要： 目的：系统评价托法替尼治疗关节病型银屑病的疗效及安全性。方法：在中国知网（CNKI）、万方（WF）、维普（VIP）、中国生物医学文献（CBM）、PubMed、Embase、Cochrane Library等数据库检索托法替尼治疗关节病型银屑病的随机对照试验（RCT），提取数据资料行Meta分析。结果：共纳入3项RCT研究，包括914例关节病型银屑病患者。Meta分析结果显示，托法替尼组5 mg组及10 mg组疗效明显优于安慰剂组，主要结局指标ACR 20、ACR 50、ACR 70缓解率，PASI 75缓解率，指（趾）炎缓解率，附着点炎缓解率差异有统计学意义（均P＜0.05），且托法替尼10 mg组与托法替尼5 mg组比较，疗效差异无统计学意义（P＞0.05）。安全性分析方面，托法替尼组与安慰剂组比较，总的不良反应、严重不良反应、严重感染、带状疱疹病毒感染、机会性感染发生率差异均无统计学意义（均P＞0.05），且托法替尼10 mg组与托法替尼5 mg组比较，不良反应发生率差异无统计学意义（P＞0.05）。结论：托法替尼治疗关节病型银屑病疗效显著，安全性良好。

关键词: 托法替尼；关节病型银屑病, 随机对照试验；Meta分析

Abstract: Objective: To evaluate the efficacy and safety of tofacitinib in the treatment of psoriatic arthritis. Methods: All randomized controlled trials (RCT) of tofacitinib in the treatment of psoriatic arthritis were searched in CNKI,Wanfang,VIP,CBM,Pubmed,Embase,The Cochrane Library. Meta analysis was performed after extracting the data. Results: Three RCTs with a total of 914 patients were included. Meta analysis results showed that the efficacy of tofacitinib 5mg group and tofacitinib 10mg group was significantly higher than that of the placebo group，including the primary outcome of ACR20, ACR50,ACR70,PASI75, dactylitis and  enthesitis inflammation remission rate（Ps＜0.05）.There was no statistical significance in the efficacy between tofacitinib 10mg group and tofacitinib 5mg group（P＞0.05）. There was no statistical significance in the incidence of any adverse event,serious adverse event,serious infection,herpes zoster infectionsand opportunistic infection（Ps＞0.05）between tofacitinib group and placebo group. There was no statistical significance in the incidence of adverse eventbetween tofacitinib 10mg group and tofacitinib 5mg group（P＞0.05）. Conclusion: Tofacitinib is effective and safe in the treatment of psoriatic arthritis.

Key words: tofacitinib , psoriatic arthritis , randomized controlled trials ;meta analysis